Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma

Phase 3

Conditions: Sarcoma

Interventions: Biological: dactinomycin
Drug: doxorubicin hydrochloride
Drug: busulfan
Drug: etoposide
Drug: ifosfamide
Drug: vincristine sulfate
Procedure: conventional surgery
Drug: melphalan
Radiation: radiation therapy
Procedure: autologous hematopoietic stem cell transplantation

First Posted Date: 2003-01-27

Last Posted Date: 2014-06-24

Lead Sponsor: University of Leicester

Target Recruit Count: 1200

Registration Number: NCT00020566

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
🇺🇸
West Virginia University Health Sciences Center - Charleston, Charleston, West Virginia, United States

and more 100 locations

Combination Chemotherapy With or Without Filgrastim Before Surgery, High-Dose Chemotherapy, and Radiation Therapy Followed by Isotretinoin With or Without Monoclonal Antibody in Treating Patients With Neuroblastoma

Phase 3

Conditions: Neuroblastoma

First Posted Date: 2003-01-27

Last Posted Date: 2014-06-24

Lead Sponsor: University of Leicester

Target Recruit Count: 175

Registration Number: NCT00030719

Locations: 🇧🇪
Universitair Ziekenhuis Gent, Ghent, Belgium
🇳🇴
Rikshospitalet University Hospital, Oslo, Norway
🇬🇧
Birmingham Children's Hospital, Birmingham, England, United Kingdom

and more 28 locations

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Phase 2

Completed

Conditions: Leukemia

First Posted Date: 2003-01-27

Last Posted Date: 2019-11-04

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 22

Registration Number: NCT00003727

Locations: 🇺🇸
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

Phase 1

Terminated

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2003-01-27

Last Posted Date: 2019-04-05

Lead Sponsor: Seattle Children's Hospital

Target Recruit Count: 24

Registration Number: NCT00003194

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States

Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Biological: Autologous dendritic cell-adenovirus p53 vaccine
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2003-01-27

Last Posted Date: 2014-05-09

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 56

Registration Number: NCT00049218

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Combination Chemotherapy Plus Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002697

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors

First Posted Date: 2003-01-27

Last Posted Date: 2017-07-11

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT00047281

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States